Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

In vivo efficacy of platelet-delivered, high specific activity factor VIII variants.

Greene TK, Wang C, Hirsch JD, Zhai L, Gewirtz J, Thornton MA, Miao HZ, Pipe SW, Kaufman RJ, Camire RM, Arruda VR, Kowalska MA, Poncz M.

Blood. 2010 Dec 23;116(26):6114-22. doi: 10.1182/blood-2010-06-293308. Epub 2010 Sep 17.

2.

Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment.

Yarovoi HV, Kufrin D, Eslin DE, Thornton MA, Haberichter SL, Shi Q, Zhu H, Camire R, Fakharzadeh SS, Kowalska MA, Wilcox DA, Sachais BS, Montgomery RR, Poncz M.

Blood. 2003 Dec 1;102(12):4006-13. Epub 2003 Jul 24.

3.

Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy.

Greene TK, Lyde RB, Bailey SC, Lambert MP, Zhai L, Sabatino DE, Camire RM, Arruda VR, Poncz M.

J Thromb Haemost. 2014 Dec;12(12):2102-12. doi: 10.1111/jth.12749. Epub 2014 Nov 4.

4.

The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.

Shi Q, Schroeder JA, Kuether EL, Montgomery RR.

J Thromb Haemost. 2015 Jul;13(7):1301-9. doi: 10.1111/jth.13001. Epub 2015 Jun 11.

5.

The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A.

Nichols TC, Bellinger DA, Reddick RL, Smith SV, Koch GG, Davis K, Sigman J, Brinkhous KM, Griggs TR, Read MS.

Blood. 1993 May 15;81(10):2644-51.

6.

Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.

Wang X, Shin SC, Chiang AF, Khan I, Pan D, Rawlings DJ, Miao CH.

Mol Ther. 2015 Apr;23(4):617-26. doi: 10.1038/mt.2015.20. Epub 2015 Feb 6.

7.

Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice.

Zhang G, Shi Q, Fahs SA, Kuether EL, Walsh CE, Montgomery RR.

Blood. 2010 Aug 26;116(8):1235-43. doi: 10.1182/blood-2009-11-255612. Epub 2010 May 5.

8.

Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors.

Gewirtz J, Thornton MA, Rauova L, Poncz M.

J Thromb Haemost. 2008 Jul;6(7):1160-6. doi: 10.1111/j.1538-7836.2008.02992.x. Epub 2008 Jul 1.

9.

Intracellular interaction of von Willebrand factor and factor VIII depends on cellular context: lessons from platelet-expressed factor VIII.

Yarovoi H, Nurden AT, Montgomery RR, Nurden P, Poncz M.

Blood. 2005 Jun 15;105(12):4674-6. Epub 2005 Feb 24.

10.

Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots.

Neyman M, Gewirtz J, Poncz M.

Blood. 2008 Aug 15;112(4):1101-8. doi: 10.1182/blood-2008-04-152959. Epub 2008 Jun 16.

11.

Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.

Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR.

J Clin Invest. 2006 Jul;116(7):1974-82.

12.

A ferric chloride induced arterial injury model used as haemostatic effect model.

Møller F, Tranholm M.

Haemophilia. 2010 Jan;16(1):e216-22. doi: 10.1111/j.1365-2516.2009.02133.x. Epub 2009 Oct 30.

PMID:
19878330
13.

Porcine model of hemophilia A.

Kashiwakura Y, Mimuro J, Onishi A, Iwamoto M, Madoiwa S, Fuchimoto D, Suzuki S, Suzuki M, Sembon S, Ishiwata A, Yasumoto A, Sakata A, Ohmori T, Hashimoto M, Yazaki S, Sakata Y.

PLoS One. 2012;7(11):e49450. doi: 10.1371/journal.pone.0049450. Epub 2012 Nov 28.

14.

Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia.

Maroney SA, Cooley BC, Ferrel JP, Bonesho CE, Nielsen LV, Johansen PB, Hermit MB, Petersen LC, Mast AE.

Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3927-31. doi: 10.1073/pnas.1119858109. Epub 2012 Feb 21.

15.

Platelet and endothelial expression of clotting factors for the treatment of hemophilia.

Montgomery RR, Shi Q.

Thromb Res. 2012 May;129 Suppl 2:S46-8. doi: 10.1016/j.thromres.2012.02.031. Epub 2012 Mar 14. Review.

16.

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A.

Du LM, Nurden P, Nurden AT, Nichols TC, Bellinger DA, Jensen ES, Haberichter SL, Merricks E, Raymer RA, Fang J, Koukouritaki SB, Jacobi PM, Hawkins TB, Cornetta K, Shi Q, Wilcox DA.

Nat Commun. 2013;4:2773. doi: 10.1038/ncomms3773.

17.

Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.

Damon AL, Scudder LE, Gnatenko DV, Sitaraman V, Hearing P, Jesty J, Bahou WF.

Thromb Haemost. 2008 Dec;100(6):1111-22.

PMID:
19132238
18.

A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(®)).

Pastoft AE, Lykkesfeldt J, Ezban M, Tranholm M, Whinna HC, Lauritzen B.

Haemophilia. 2012 Sep;18(5):782-8. doi: 10.1111/j.1365-2516.2012.02780.x. Epub 2012 Apr 16.

PMID:
22500820
19.

Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets.

Kufrin D, Eslin DE, Bdeir K, Murciano JC, Kuo A, Kowalska MA, Degen JL, Sachais BS, Cines DB, Poncz M.

Blood. 2003 Aug 1;102(3):926-33. Epub 2003 Apr 10.

20.

Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis.

Lei X, Reheman A, Hou Y, Zhou H, Wang Y, Marshall AH, Liang C, Dai X, Li BX, Vanhoorelbeke K, Ni H.

Thromb Haemost. 2014 Feb;111(2):279-89. doi: 10.1160/TH13-06-0490. Epub 2013 Oct 31.

PMID:
24172860

Supplemental Content

Support Center